Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Invested Capital (2019 - 2025)

Historic Invested Capital for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $972.5 million.

  • Beam Therapeutics' Invested Capital rose 2160.58% to $972.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $972.5 million, marking a year-over-year increase of 2160.58%. This contributed to the annual value of $741.9 million for FY2024, which is 2521.69% down from last year.
  • Per Beam Therapeutics' latest filing, its Invested Capital stood at $972.5 million for Q3 2025, which was up 2160.58% from $1.1 billion recorded in Q2 2025.
  • Beam Therapeutics' 5-year Invested Capital high stood at $1.1 billion for Q1 2025, and its period low was $495.5 million during Q1 2021.
  • Moreover, its 5-year median value for Invested Capital was $825.2 million (2023), whereas its average is $838.2 million.
  • As far as peak fluctuations go, Beam Therapeutics' Invested Capital skyrocketed by 31714.45% in 2021, and later crashed by 2521.69% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Invested Capital stood at $868.9 million in 2021, then fell by 13.48% to $751.8 million in 2022, then soared by 31.97% to $992.1 million in 2023, then dropped by 25.22% to $741.9 million in 2024, then soared by 31.07% to $972.5 million in 2025.
  • Its Invested Capital stands at $972.5 million for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.